Shattuck Labs, Inc.
No enriched coverage for $STTK in the last 7 days.
No SEC Form 4 filings for $STTK in the last 30 days.
See all $STTK insider activity →H.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.
Shattuck Labs, Inc. (STTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sttk_2q2026earningsrelease.htm EX-99.1 Document Exhibit 99.1 Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights – Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism i
Shattuck Labs (STTK) shares fell 1.8% pre-open after its Q2 2026 earnings. The company reported a net loss of $15.2 million versus $12.5 million a year earlier, and R&D rose 34% to $11.7 million. It cited favorable Phase 1 safety for SL-325 and said Phase 2b in Crohn’s is on track. Cash and investments were about $208.3 million.
Recent STTK coverage spans financial news, earnings and technology.
Lower PT tied to trial expansion details and ongoing Crohn’s and DR3 x IL-23 program timelines, plus concurrent equity financing signals.
Clinical Phase 1 readout plus a stated Phase 2b start timeline and extended cash runway are likely to re-rate near-term probability of success.
Earnings show worsening cost profile and no revenue beat, but clinical Phase 1 SL-325 safety and durability plus Phase 2b timing are supportive.
Clinical Phase 1 readout plus a scheduled Phase 2b start date and extended cash runway are likely to support risk-on positioning, while investors will still wait for 2028 efficacy data.
The stock’s move is attributed to a fresh analyst initiation with a materially higher price target, reinforcing near-term sentiment around SL-325.
alphai scores every news story that mentions STTK with an AI model for sentiment and relevance, and aggregates insider trades from Shattuck Labs, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
H.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.
4 min readShattuck Labs, Inc. (STTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sttk_2q2026earningsrelease.htm EX-99.1 Document Exhibit 99.1 Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights – Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism i
6 min readShattuck Labs (STTK) shares fell 1.8% pre-open after its Q2 2026 earnings. The company reported a net loss of $15.2 million versus $12.5 million a year earlier, and R&D rose 34% to $11.7 million. It cited favorable Phase 1 safety for SL-325 and said Phase 2b in Crohn’s is on track. Cash and investments were about $208.3 million.
5 min readShattuck Labs (NASDAQ: STTK) reported Q2 2026 results and clinical updates for SL-325 and SL-846. SL-325 Phase 1 showed a favorable safety profile, 3.7% antidrug antibodies, and durable TL1A/DR3 blockade; RECEPTIVE-CD1 Phase 2b in Crohn’s is expected to start Q3 2026. Cash and investments were $208.3M, funding operations into 2029.
7 min readShattuck Labs shares rose about 4.8% on Friday, closing near $7.43. The move followed an inaugural note from JPMorgan’s Brian Cheng, who rated STTK overweight and set a $10 price target. The note cited Shattuck’s lead IBD drug candidate SL-325, referencing recent healthy volunteer data on safety and target engagement.
3 min readWall Street analysts issued multiple rating changes. Truist upgraded PayPal (PYPL) to Hold, $57 target; Leerink upgraded Edwards Lifesciences (EW) to Outperform, $101. TD Cowen upgraded Digital Realty (DLR) to Buy, $222; Morgan Stanley upgraded Progressive (PGR) to Equal Weight, $210. Several downgrades followed, including Infosys (INFY) and Albertsons (ACI). Coverage initiations included SpaceX (SPCX) and Chime (CHYM).
2 min read24/7 Wall St. compiled Friday analyst research calls amid a risk-off session. It cites major index declines and higher Treasury yields, oil, and lower gold. Analyst actions include upgrades for CLF, DLR, DOV, PYPL, PRG; downgrades for ACI, CAKE, FLYW, PAG, TENB; and initiations for OBDC, CHYM, STTK, SPCX, SUNC with stated price targets.
4 min readSIEGALL CLAY B purchased 62,500 shares of Shattuck Labs, Inc. (STTK) at $4.00 ($0.25M total) on 2026-06-09.
1 min readShattuck Labs, Inc. (STTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d163713dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Execution Version Shattuck Labs, Inc. 10,879,376 Shares of Common Stock Pre-Funded Warrants to Purchase 7,870,624 Shares of Common Stock ($0.0001 par value) Underwriting Agreement June 9, 2026 Leerink Partners LLC J.P. Morgan Se
3 min readShattuck Labs (STTK) priced its previously announced public offering of 10.88 million shares at $4.00 each, and said it will also issue pre-funded warrants for up to 7.87 million shares at $3.9999 per warrant. The company expects about $75 million in gross proceeds and said the deal should close June 11. Underwriters have a 30-day option for up to 2.81 million additional shares.
2 min read
